Systematic review. Pancreatic involvement in inflammatory bowel disease (IBD). The wide spectrum of pancreatic involvement in patients with IBD may represent a challenge. From the 124 studies analyzed, acute pancreatitis (AP) is the most frequent pancreatic manifestation in IBD; the majority of AP cases in IBD are due to gallstones and drugs, but cases of idiopathic AP are increasingly reported. Autoimmune pancreatisis is a rare disease, but a strong association with IBD has been demonstrated, especially for type 2 and ulcerative colitis.

Significant improvements regarding IBS symptoms were seen for patients receiving individual or group hypnotherapy, with no differences between the groups.

Relative to conventional care, opioid agonist therapy clients offered point-of-care hepatitis c virus RNA testing and treatment with DAAs at their community pharmacy had higher odds of being tested, starting treatment, and obtaining a cure.

The current multicentre study demonstrated the non-inferior efficacy of keverprazan to lansoprazole in treating erosive oesophagitis. The incidences of drug-related adverse events were comparable between keverprazan and lansoprazole.

Based on therapy starting age and duration, HBsAg level and infection length, a high likelihood of a functional HBV specific CD8+ cell response during nucleos(t)ide analogue treatment foresees HBV control after treatment discontinuation.

Anatomic axial T2-weighted MR images without (A) and with (B) fat saturation in an asymptomatic patient with IPAA show an intersphincteric perianal fistula (arrow) with internal opening below the level of the anastomosis.

Older-onset ulcerative colitis is associated with a lower effectiveness of intravenous steroids with higher risk of colectomy and adverse events.